全脑放疗联合替莫唑胺化疗方案治疗脑转移瘤的效果及安全性分析  

Efficacy and safety analysis of whole brain radiotherapy combined with te mozolomide chemotherapy in the treatment of brain metastases

作　　者：黎小姿 LI Xiaozi(Hechi People’s Hospital,Hechi 547000,Guangxi,China)

机构地区：[1]河池市人民医院,广西河池547000

出　　处：《当代医药论丛》2022年第2期18-21,共4页

摘　　要：目的:分析用全脑放疗(WBRT)联合替莫唑胺化疗方案治疗脑转移瘤的效果及安全性。方法:选择河池市人民医院收治的86例脑转移瘤患者作为研究对象。按照随机数表法将其分为T组与B组。用WBRT对B组患者进行治疗,用WBRT联合替莫唑胺化疗方案对T组患者进行治疗,然后比较两组患者的临床疗效、无进展生存时间、中位生存时间及不良反应的发生率。结果:T组患者治疗的总有效率高于B组患者,P<0.05。治疗后,T组患者的无进展生存时间和中位生存时间均长于B组患者,P<0.05。治疗期间,两组患者不良反应的发生率相比,P>0.05。结论:用WBRT联合替莫唑胺化疗方案治疗脑转移瘤的效果显著,能缓解患者的病情,延长其生存时间,且治疗的安全性较高。Objective:To analyze the efficacy and safety of whole brain radiotherapy(WBRT)combined with temozolomide chemotherapy in the treatment of brain metastases.Methods:a total of 86 patients with brain metastases admitted to Hechi People’s Hospital were selected as the research object.They were divided into T group and B group according to random table method.Patients in group B were treated with WBRT,and patients in group T were treated with WBRT combined with temozolomide chemotherapy,and the clinical efficacy,progression-free survival time,median survival time,and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of T group was higher than that of B group,P<0.05.After treatment,the progression-free survival time and median survival time of patients in T group were longer than those in B group,P<0.05.During treatment,the incidence of adverse reactions in 2 groups was compared,P>0.05.Conclusion:WBRT combined with temozolomide chemotherapy has a significant effect on the treatment of brain metastases,which can alleviate the disease of patients and prolong their surviva l time,and the safety of treatment is high.

关 键 词：全脑放疗 替莫唑胺 化疗 脑转移瘤 不良反应 

分 类 号：R739.41[医药卫生—肿瘤]